marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-12-2024
Maravai LifeSciences Holdings Balance Sheet 2011-2024 | MRVI
Annual Balance Sheet Maravai LifeSciences Holdings
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-49.5 M | -104 M | -23 M | 164 M | 313 M | 316 M | - | - | - | - | - | - | - |
Long Term Debt |
519 M | 522 M | 525 M | 400 M | 335 M | 336 M | - | - | - | - | - | - | - |
Long Term Debt Current |
6.78 M | 6.27 M | 3.72 M | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 404 M | 356 M | - | - | - | - | - | - | - |
Total Current Liabilities |
87.5 M | 110 M | 93.8 M | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
698 M | 1.38 B | 1.37 B | 1.12 B | 433 M | 392 M | - | - | - | - | - | - | - |
Deferred Revenue |
3.36 M | 3.09 M | 10.2 M | 78.1 M | 841 K | 1.09 M | - | - | - | - | - | - | - |
Retained Earnings |
286 M | 405 M | 185 M | 854 K | -42.4 M | -38.2 M | - | - | - | - | - | - | - |
Total Assets |
1.49 B | 2.28 B | 1.92 B | 1.27 B | 578 M | 540 M | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
575 M | 632 M | 551 M | 236 M | - | - | - | - | - | - | - | - | - |
Book Value |
790 M | 905 M | 545 M | 155 M | 145 M | 148 M | - | - | - | - | - | - | - |
Total Shareholders Equity |
417 M | 545 M | 545 M | 155 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Maravai LifeSciences Holdings
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
516 M | 517 M | 518 M | 520 M | 520 M | 521 M | 522 M | - | - | 524 M | 525 M | 526 M | 527 M | 528 M | 529 M | 529 M | 529 M | 529 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
665 M | 671 M | 667 M | 1.38 B | 1.37 B | 1.41 B | 1.38 B | - | - | 1.39 B | 1.37 B | 1.44 B | 1.27 B | 1.14 B | 1.12 B | 1.12 B | 1.12 B | 1.12 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
1.83 M | 2.08 M | 2.21 M | 2.55 M | 2.46 M | 2.05 M | 3.09 M | - | - | 3.69 M | 10.2 M | 66.7 M | 109 M | 119 M | 78.1 M | 78.1 M | 78.1 M | 78.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
167 M | 266 M | 274 M | 392 M | 398 M | 405 M | 405 M | - | - | 251 M | 185 M | 127 M | 73.2 M | 25.6 M | 854 K | 854 K | 854 K | 854 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
1.28 B | 1.45 B | 1.44 B | 2.27 B | 2.26 B | 2.32 B | 2.28 B | - | - | 2.04 B | 1.92 B | 1.89 B | 1.6 B | 1.35 B | 1.27 B | 1.27 B | 1.27 B | 1.27 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
578 M | 573 M | 562 M | 580 M | 580 M | 628 M | 632 M | 617 M | 551 M | 431 M | 551 M | 548 M | 375 M | 248 M | 236 M | 236 M | 236 M | 236 M | 24.7 M | - | - | - | 21.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
613 M | 776 M | 777 M | 892 M | 898 M | 901 M | 905 M | - | - | 654 M | 545 M | 454 M | 333 M | 210 M | 155 M | 155 M | 155 M | 155 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
345 M | 437 M | 411 M | 892 M | 898 M | 901 M | 545 M | 842 M | 774 M | 654 M | 315 M | 303 M | 194 M | 113 M | 88.5 M | 88.5 M | 88.5 M | 88.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency